Off-label second generation antipsychotics for impulse regulation disorders: A review

Psychopharmacology Bulletin

Volumn 43, Issue 3, 2010, Pages 45-81

  Scheltema Beduin, Albertine ^a   De Haan, Lieuwe ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Impulse regulation disorders; Off label; Second generation antipsychotics; Substance use disorders

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; CHILD CARE; DEPRESSION; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMPULSE CONTROL DISORDER; LONG TERM CARE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; POSTTRAUMATIC STRESS DISORDER; PRESCRIPTION; PSYCHOSIS; PSYCHOSOCIAL DISORDER; SCHIZOPHRENIA; SUBSTANCE ABUSE; TIC; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; EVIDENCE-BASED MEDICINE; HUMANS; IMPULSE CONTROL DISORDERS; OFF-LABEL USE; SUBSTANCE-RELATED DISORDERS; TIC DISORDERS; TREATMENT OUTCOME;

EID: 79953011362     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (140)

1. Kjelsberg E. Conduct disordered adolescents hospitalised 1963-1990. Secular trends in criminal activity. Eur Child Adolesc Psychiatry 2005;14(4):191-199.
2. Larm P, Hodgins S, Larsson A, Samuelson YM, Tengstrom A. Long-term outcomes of adolescents treated for substance misuse. Drug Alcohol Depend 2008;96(1-2):79-89.
3. Burke JD, Loeber R, Birmaher B. Oppositional defiant disorder and conduct disorder: a review of the past 10 years, part II. J Am Acad Child Adolesc Psychiatry 2002;41(11):1275-1293. (Pubitemid 38338019)
4. Volkow ND. Drug abuse and mental illness: progress in understanding comorbidity. Am J Psychiatry 2001;158(8):1181-1183. (Pubitemid 32717687)
5. Chambers RA,Taylor JR, Potenza MN. Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003;160(6):1041-1052. (Pubitemid 41070962)
6. Nimwegen Lv, de Haan Ld, Beveren Nv, Brink Wvd, Linszen D. Adolescence, schizophrenia and drug abuse: a window of vulnerability. Acta Psychiatr Scand Suppl 2005;(427):35-42. (Pubitemid 40780198)
7. Frank B, Gupta S, McGlynn DJ. Psychotropic medications and informed consent: a review. Ann Clin Psychiatry 2008;20(2):87-95. (Pubitemid 351892646)
8. Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, Martin BC. Off-label use of antide-pressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry 2006;67(6):972-982. (Pubitemid 44049097)
9. Garattini S, Bertele' V. The impact of European regulatory policies on psychotropic drug prescribing patterns. Int Rev Psychiatry 2005;17(3):199-204. (Pubitemid 40827297)
10. Meadows WA, Hollowell BD. 'Off-label' drug use: an FDA regulatory term, not a negative implication of its medical use. Int J Impot Res 2008;20(2):135-144. (Pubitemid 351374335)
11. Kramer S, McCall W. Off-label prescribing: 7 steps for safer, more effective treatment. Current Psychiatry 1-5-2006;5(4):14-30. Current Psychiatry LLC.
12. Kelly DL, Love RC, MacKowick M, McMahon RP, Conley RR. Atypical antipsychotic use in a state hospital inpatient adolescent population. J Child Adolesc Psychopharmacol 2004;14(1):75-85. (Pubitemid 38525956)
13. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004;158(8):753-759. (Pubitemid 39025073)
14. Rosenheck RA, Leslie DL, Doshi JA. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatr Serv 2008;59(5):515-520.
15. Philip NS, Carpenter LL, Tyrka AR, Price LH. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. J Psychiatr Pract 2008;14(1):34-44. (Pubitemid 351158846)
16. Pae CU, Lim HK, Peindl K et al. The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Clin Psychopharmacol 2008;23(1):1-8. (Pubitemid 350294864)
17. Pae CU, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 2008;22(5):367-388. (Pubitemid 351508122)
18. West L, Waldrop J, Brunssen S. Pharmacologic treatment for the core deficits and associated symptoms of autism in children. J Pediatr Health Care 2009;23(2):75-89.
19. Chouinard G. The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J Psychiatry Neurosci 2006;31(3):168-176. (Pubitemid 43954735)
20. Kronenberger WG, Giauque AL, Lafata DE, Bohnstedt BN, Maxey LE, Dunn DW. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/ oppositional-defiant disorder, and aggression: a prospective, open-label study. J Child Adolesc Psychopharmacol 2007;17(3):334-347. (Pubitemid 47067957)
21. University of Michigan Health System-Academic Institution. Attention-deficit hyperactivity disorder. [NGC:004590]. 2005.
22. National Collaborating Centre for Mental Health-National Government Agency [Non-U.S. Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. [NGC:005015]. 2006.
23. American Academy of Child and Adolescent Psychiatry - Medical Specialty Society. Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. [NGC:005513]. 2007.
24. Kutcher S, Aman M, Brooks SJ et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 2004;14(1):11-28. (Pubitemid 37495027)
25. Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry 2006;63(6):679-685. (Pubitemid 43848299)
26. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008;121(5):1002-1009.
27. Olfson M. Antipsychotic prescriptions for children and adolescents in the UK increased from 1993 to 2005. Evid Based Ment Health 2009;12(1):30.
28. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv 2008;59(5):507-514.
29. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry 2001;158(11):1783-1793. (Pubitemid 33054770)
30. Romer D, Betancourt L, Giannetta JM, Brodsky NL, Farah M, Hurt H. Executive Cognitive Functions and Impulsivity as Correlates of Risk Taking and Problem Behavior in Preadolescents. Neuropsychologia 2009.
31. Crews FT, Boettiger CA. Impulsivity, frontal lobes and risk for addiction. Pharmacol Biochem Behav 2009;93(3):237-247.
32. Wit dH. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 2009;14(1):22-31.
33. White JL, Moffitt TE, Caspi A, Bartusch DJ, Needles DJ, Stouthamer-Loeber M. Measuring impul- sivity and examining its relationship to delinquency. J Abnorm Psychol 1994;103(2):192-205. (Pubitemid 24152793)
34. American Psychiatric Association. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders (4th ed., revised). Washington, DC. 2000.
35. Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer JL. A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000;39(4):509-516. (Pubitemid 30185547)
36. Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry2007;46(5): 558-565. (Pubitemid 46642572)
37. Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo- controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006;163(3):402-410. (Pubitemid 44469381)
38. Ad-Dab'bagh Y, Greenfield B, Milne-Smith J, Freedman H. Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy. Can J Psychiatry2000;45(4):376-382. (Pubitemid 30367435)
39. Haas M, Karcher K, Pandina GJ. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. J Child Adolesc Psychopharmacol 2008;18(4):337-345.
40. Findling RL, Reed MD, O'Riordan MA, Demeter CA, Stansbrey RJ, McNamara NK. Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry 2006;45(7):792-800. (Pubitemid 43932905)
41. Bastiaens L. A non-randomized, open study with aripiprazole and ziprasidone for the treatment of aggressive behavior in youth in a community clinic. Community Ment Health J 2009;45(1):73-77.
42. Findling RL, Blumer JL, Kauffman R et al. Aripiprazole in pediatric conduct disorder: a pilot study [abstract]. Eur Neuropsychopharmacol, 2003;13 (suppl 4):S335.
43. Findling RL, Short EJ, Leskovec T et al. Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008;18(4):347-354.
44. Soderstrom H, Rastam M, Gillberg C. A clinical case series of six extremely aggressive youths treated with olanzapine. Eur Child Adolesc Psychiatry 2002;11(3):138-141.
45. Bellinghen M. van, Troch C. de. Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol 2001;11(1):5-13. (Pubitemid 32295178)
46. Aman MG, De SG, Derivan A, Lyons B, Findling RL. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159(8):1337-1346. (Pubitemid 34832715)
47. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41(9):1026-1036. (Pubitemid 38338050)
48. Hellings JA, Zarcone JR, Reese RM et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord 2006;36(3):401-411. (Pubitemid 43828664)
49. Tyrer P, Oliver-Africano PC, Ahmed Z et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet 2008;371(9606):57-63.
50. Findling RL, Aman MG, Eerdekens M, Derivan A, Lyons B. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004;161(4):677-684. (Pubitemid 38445512)
51. Reyes M, Olah R, Csaba K, Augustyns I, Eerdekens M. Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study. Eur Child Adolesc Psychiatry 2006;15(2):97-104. (Pubitemid 43352183)
52. Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol 2000;10(1):19-26. (Pubitemid 30155424)
53. Reyes M, Croonenberghs J, Augustyns I, Eerdekens M. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 2006;16(3):260-272. (Pubitemid 43902423)
54. Croonenberghs J, Fegert JM, Findling RL, De SG, Van DS. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients. J Am Acad Child Adolesc Psychiatry 2005;44(1):64-72. (Pubitemid 40019201)
55. Holford LE, Van der Walt A, Peter E. Risperidone for behavior disorders in children with mental retardation. In: Scientific Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, XVI:118. 2000.
56. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics 2002;110(3):e34.
57. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. J Clin Psychiatry 2003;64(1):60-62. (Pubitemid 36182231)
58. Valicenti-McDermott MR, Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 2006;16(5):549-560. (Pubitemid 44737210)
59. Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002;22(1):31-39. (Pubitemid 34101290)
60. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003;60(7):1130-1135. (Pubitemid 36418773)
61. Bruggeman R, van der LC, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Risperidone versus pimozide inTourette's disorder: a comparative double-blind parallel-group study. J Clin Psychiatry 2001;62(1):50-56. (Pubitemid 32154319)
62. Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 2002;41(3):330-336. (Pubitemid 38338155)
63. Onofrj M, Paci C, D'Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000;247(6):443-446. (Pubitemid 30433558)
64. Sallee FR, Kurlan R, Goetz CG et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry 2000;39(3):292-299. (Pubitemid 30127607)
65. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136(3):317-320. (Pubitemid 9153307)
66. Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry 2001;62(4):290-294. (Pubitemid 32428769)
67. Lombroso PJ, Scahill L, King RA et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995;34(9):1147-1152.
68. Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC. Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. J Child Adolesc Psychopharmacol 2005;15(2):318-324.
69. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 2003;13(3):295-299. (Pubitemid 37288529)
70. Stamenkovic M, Schindler SD, Aschauer HN et al. Effective open-label treatment of tourette's disorder with olanzapine. Int Clin Psychopharmacol 2000;15(1):23-28. (Pubitemid 30058135)
71. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996;57(1):29-31. (Pubitemid 26030525)
72. Bengi Semerci Z. Olanzapine in Tourette's disorder. J Am Acad Child Adolesc Psychiatry 2000;39(2):140.
73. Parraga HC, Parraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol 2001;11(2):187-191. (Pubitemid 32588491)
74. Bhadrinath BR. Olanzapine in Tourette syndrome. Br J Psychiatry1998;172: 366.
75. Chan-Ob T, Kuntawongse N, Boonyanaruthee V. Quetiapine for tic disorder: a case report. J Med Assoc Thai 2001;84(11):1624-1628. (Pubitemid 34437031)
76. Padala PR, Qadri SF, Madaan V. Aripiprazole for the treatment of Tourette's disorder. Prim Care Companion J Clin Psychiatry 2005;7(6):296-299. (Pubitemid 44371610)
77. Schaller JL, Behar D. Quetiapine treatment of adolescent and child tic disorders. Two case reports. Eur Child Adolesc Psychiatry 2002;11(4):196-197. (Pubitemid 35429340)
78. Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in tourette syndrome with aripipra- zole. J Clin Psychopharmacol 2005;25(1):94-96. (Pubitemid 40129390)
79. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette's syndrome. Lancet 1994;344(8936):1577-1578.
80. Giakas WJ. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive- compulsive disorder. Am J Psychiatry 1995;152(7):1097-1098.
81. Shulman LM, Singer C, Weiner WJ. Risperidone in Gilles de la Tourette syndrome. Neurology 1995;45(7):1419.
82. Karam-Hage M, Ghaziuddin N. Olanzapine in Tourette's disorder. J Am Acad Child Adolesc Psychiatry 2000;39(2):139.
83. Meisel A, Winter C, Zschenderlein R, Arnold G. Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Mov Disord 2004;19(8):991-992. (Pubitemid 39199278)
84. Owen R, Sikich L, Marcus RN et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124(6):1533-1540.
85. Marcus RN, Owen R, Kamen L et al. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 2009;48(11):1110-1119.
86. Hollander E, Wasserman S, Swanson EN et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16(5):541-548. (Pubitemid 44737209)
87. Findling RL, McNamara NK, Gracious BL et al. Quetiapine in nine youths with autistic disorder. JChild Adolesc Psychopharmacol 2004;14(2):287-294. (Pubitemid 38988794)
88. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9(2):99-107. (Pubitemid 29379846)
89. Corson AH, Barkenbus JE, Posey DJ, Stigler KA, McDougle CJ. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004;65(11):1531-1536.
90. Hardan AY, Jou RJ, Handen BL. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 2005;35(3):387-391. (Pubitemid 41125976)
91. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40(8):887-894. (Pubitemid 32667070)
92. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19(1):37-44. (Pubitemid 29047329)
93. Kemner C, Willemsen-Swinkels SH, de JM, Tuynman-Qua H, van EH. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22(5):455-460.
94. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004;65(1):110-113.
95. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder. Am J Psychiatry1996;153(5):738.
96. Gobbi G, Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour. J Psychiatry Neurosci 2001;26(4):340-341. (Pubitemid 32912430)
97. Chen NC, Bedair HS, McKay B, Bowers MB, Jr., Mazure C. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 2001;62(6):479-480. (Pubitemid 32717889)
98. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997;36(9):1166-1167.
99. Stavrakaki C, Antochi R, Emery PC. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci 2004;29(1):57-60. (Pubitemid 38570013)
100. Duggal HS. Ziprasidone for maladaptive behavior and attention-deficit/ hyperactivity disorder symptoms in autistic disorder. J Child Adolesc Psychopharmacol 2007;17(2):261-263. (Pubitemid 46828924)
101. McDougle CJ, Kem DL, Posey DJ. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41(8):921-927. (Pubitemid 38338071)
102. Goforth HW, Rao MS. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry 2003;37(6):775-776. (Pubitemid 38072527)
103. Guardia J, Segura L, Gonzalvo B et al. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res 2004;28(5):736-745. (Pubitemid 38661370)
104. Hutchison KE, Ray L, Sandman E et al. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 2006;31(6):1310-1317. (Pubitemid 43971847)
105. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol 2008;28(1):5-12.
106. Martinotti G, Di NM, Di GM, Janiri L. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone. J Psychopharmacol 2009;23(2):123-129.
107. Kampman KM, Pettinati HM, Lynch KG et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J Clin Psychopharmacol 2007;27(4):344-351. (Pubitemid 47075504)
108. Grabowski J, Rhoades H, Silverman P et al. Risperidone for the treatment of cocaine dependence: randomized, double-blind trial. J Clin Psychopharmacol 2000;20(3):305-310. (Pubitemid 30318358)
109. Grabowski J, Rhoades H, Stotts A et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29(5):969-981. (Pubitemid 38526797)
110. 110.Smelson DA, Williams J, Ziedonis D et al. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients. J Subst Abuse Treat 2004;27(1):45-49. (Pubitemid 38829778)
111. Loebl T, Angarita GA, Pachas GN et al. A randomized, double-blind, placebo-controlled trial of long-acting risperidone in cocaine-dependent men. J Clin Psychiatry 2008;69(3):480-486. (Pubitemid 351549404)
112. Kampman KM, Pettinati H, Lynch KG, Sparkman T, O'Brien CP. A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend 2003;70(3):265-273. (Pubitemid 36577338)
113. Reid MS, Casadonte P, Baker S et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100 (Suppl 1):43-57. (Pubitemid 40363424)
114. Hamilton JD, Nguyen QX, Gerber RM, Rubio NB. Olanzapine in cocaine dependence: a double- blind, placebo-controlled trial. Am J Addict 2009;18(1):48-52.
115. Tiihonen J, Kuoppasalmi K, Fohr J et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007;164(1):160-162. (Pubitemid 46154797)
116. Farren CK, Hameedi FA, Rosen MA, Woods S, Jatlow P, Kosten TR. Significant interaction between clozapine and cocaine in cocaine addicts. Drug Alcohol Depend 2000;59(2):153-163. (Pubitemid 30417420)
117. De La Garza R, Newton TF, Kalechstein AD. Risperidone diminishes cocaine-induced craving. Psychopharmacology (Berl) 2005;178(2-3):347-350.
118. Levin FR, McDowell D, Evans SM, Brooks D, Spano C, Nunes EV. Pergolide mesylate for cocaine abuse: a controlled preliminary trial. Am J Addict 1999;8(2):120-127. (Pubitemid 29242237)
119. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K. Risperidone pre-treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 2001;102(3):227-233. (Pubitemid 32607561)
120. Roy A, Roy M, Smelson DA. Risperidone, ERG and cocaine craving. Am J Addict1998;7(1):90. 121.
121. Sattar SP, Bhatia SC, Petty F. Potential benefits of quetiapine in the treatment of substance dependence disorders. J Psychiatry Neurosci 2004;29(6):452-457. (Pubitemid 40075716)
122. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulveda I. Quetiapine for treatment of alcohol dependence. J Clin Psychopharmacol 2004;24(5):532-535. (Pubitemid 39274208)
123. Kennedy A, Wood AE, Saxon AJ et al. Quetiapine for the treatment of cocaine dependence: an openlabel trial. J Clin Psychopharmacol 2008;28(2):221-224. (Pubitemid 351417129)
124. Martinotti G, Di NM, Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am J Drug Alcohol Abuse 2007;33(3):393-401. (Pubitemid 47037170)
125. Vorspan F, Bellais L, Keijzer L, Lepine JP. An open-label study of aripiprazole in nonschizophrenic crack-dependent patients. J Clin Psychopharmacol 2008;28(5):570-572.
126. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs 2007;21(11):911-936. (Pubitemid 47557106)
127. Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11study). Lancet 2009;374(9690):620-627.
128. Kumra S, Oberstar JV, Sikich L et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008;34(1):60-71. (Pubitemid 350262286)
129. Correll CU, Penzner JB, Parikh UH et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006;15(1):177-206. (Pubitemid 41735243)
130. Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for atypical antipsychotics: A systematic review. Ann Gen Hosp Psychiatry 2004;3(1):4.
131. Campbell M, Rapoport JL, Simpson GM. Antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry 1999;38(5):537-545. (Pubitemid 29203469)
132. Schur SB, Sikich L, Findling RL et al. Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. J Am Acad Child Adolesc Psychiatry 2003;42(2):132-144. (Pubitemid 39610593)
133. Fedorowicz VJ, Fombonne E. Metabolic side effects of a typical antipsychotics in children: a literature review. J Psychopharmacol 2005;19(5):533-550. (Pubitemid 41392308)
134. Troost PW, Lahuis BE, Steenhuis MP et al. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 2005;44(11):1137-1144. (Pubitemid 41508125)
135. Luby J, Mrakotsky C, Stalets MM et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 2006;16(5):575-587. (Pubitemid 44737212)
136. Findling RL, McNamara NK, Gracious BL. Paediatric uses of atypical antipsychotics. Expert Opin Pharmacother 2000;1(5):935-945.
137. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329(3):162-167. (Pubitemid 23195736)
138. Tauscher J, Hussain T, Agid O et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 2004;161(9):1620-1625. (Pubitemid 39201459)
139. Miller R, Wickens JR, Beninger RJ. Dopamine D-1 and D-2 receptors in relation to reward and performance: a case for the D-1 receptor as a primary site of therapeutic action of neuroleptic drugs. Prog Neurobiol 1990;34(2):143-183. (Pubitemid 20066616)
140. Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharma-cotherapeutic intervention. J Subst Abuse Treat 2008;34(1):61-71. (Pubitemid 350216350)